<DOC>
	<DOCNO>NCT00006125</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine doxorubicin topotecan treating patient relapse refractory intermediate-grade high-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Relapsed Refractory Intermediate-Grade High-Grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate time progression patient relapse refractory intermediate high grade non-Hodgkin 's lymphoma treat doxorubicin topotecan . - Determine toxicity regimen patient . OUTLINE : Patients receive doxorubicin IV 5-10 minute day 1 topotecan IV 30 minute day 3-5 . Treatment repeat every 21 day 6 course absence disease progression . Patients follow every 6 month 2 year annually next 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent refractory nonHodgkin 's lymphoma one follow subtypes : Follicular center lymphoma , grade 3 Diffuse large Bcell lymphoma Diffuse large Bcell lymphoma , primary mediastinal Bcell lymphoma Burkitt 's lymphoma High grade Bcell lymphoma , Burkittlike Anaplastic large cell lymphoma , CD30+ cell type Anaplastic large cell lymphoma , Tcell type Anaplastic large cell lymphoma , nullcell type Anaplastic large cell lymphoma , Hodgkin 's like Bidimensionally measurable disease NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL history Gilbert 's Disease AST great 2.5 time upper limit normal Renal : Creatinine normal Cardiovascular : LVEF least 45 % MUGA echocardiogram Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Greater 3 week since prior chemotherapy ( 6 week since prior nitrosoureas mitomycin ) No great 96 mg/m2 mitoxantrone No great 400 mg/m2 prior doxorubicin combine total doxorubicin mitoxantrone No prior camptothecins No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except steroid adrenal failure hormone give nondisease condition ( e.g. , insulin diabetes ) No concurrent dexamethasone steroidal antiemetic Radiotherapy : Greater 3 week since prior radiotherapy No concurrent radiotherapy except whole brain irradiation document CNS disease Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>